Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?
The PRIME Institute of the College of Pharmacy, University of Minnesota, recently released preliminary research findings indicating a trend of extraordinary pharmaceutical industry pricing of drug products in the United States (U.S.). According to researchers at the PRIME Institute, such extraordina...
| 主要作者: | |
|---|---|
| 格式: | 電子 Article |
| 語言: | English |
| Check availability: | HBZ Gateway |
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| 出版: |
2010
|
| In: |
Journal of business ethics
Year: 2010, 卷: 94, 發布: 2, Pages: 225-242 |
| Further subjects: | B
Biotechnology Industry Organization
B extraordinary pricing B 企業社會責任 B orphan drugs B Pharmaceutical Industry B Reputation B Pharmaceutical Research and Manufacturers of America B National Organization for Rare Disorders B patient access B pharmaceutical pricing B Inc |
| 在線閱讀: |
Volltext (JSTOR) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1785638785 | ||
| 003 | DE-627 | ||
| 005 | 20250324045332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220112s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10551-009-0259-x |2 doi | |
| 035 | |a (DE-627)1785638785 | ||
| 035 | |a (DE-599)KXP1785638785 | ||
| 035 | |a (DE-He213)s10551-009-0259-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |8 1\p |e VerfasserIn |0 (DE-588)171240669 |0 (DE-627)06142143X |0 (DE-576)132049309 |4 aut |a Hemphill, Thomas A. | |
| 109 | |a Hemphill, Thomas A. |a Hemphill, T. A. | ||
| 245 | 1 | 0 | |a Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry? |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The PRIME Institute of the College of Pharmacy, University of Minnesota, recently released preliminary research findings indicating a trend of extraordinary pharmaceutical industry pricing of drug products in the United States (U.S.). According to researchers at the PRIME Institute, such extraordinary price increases are defined as any price increase that is equal to, or greater than, 100% at a single point in time. In some instances, PRIME Institute researchers found that drugs exhibiting extraordinary price increases are categorized as “orphan drugs” (or blood-related biologic treatments) and often life-saving or life-sustaining for treating the cause or symptoms of diseases affecting fewer than 200,000 people in the U.S., or where there is prevalence of less than 5 per 10,000 people afflicted with a disease or symptoms in the community. Because of extraordinary price increases for orphan drugs – some exceeding 1000% at a single point in time – this article addresses two interrelated questions: Are extraordinary orphan drug price increases socially responsible behavior? If so, are the pharmaceutical industry's policies providing orphan drug access to American consumers in dire need of available life-sustaining and life-enhancing pharmaceuticals considered “socially responsible” behavior? The author concludes, after an interdisciplinary analysis of the legal, economic, sociopolitical, and ethical dimensions of orphan drug pricing, that they are not socially responsible – unless justified by cost and availability of health care marketplace/patient options. Furthermore, the author recommends a socially responsible industry strategic approach to insure that patients ultimately receive – regardless of cost – timely access to life-saving and life-sustaining orphan drugs. | ||
| 601 | |a Strategie | ||
| 601 | |a Industrie | ||
| 650 | 4 | |a Reputation | |
| 650 | 4 | |a pharmaceutical pricing | |
| 650 | 4 | |a Pharmaceutical Industry | |
| 650 | 4 | |a Pharmaceutical Research and Manufacturers of America | |
| 650 | 4 | |a patient access | |
| 650 | 4 | |a orphan drugs | |
| 650 | 4 | |a Inc | |
| 650 | 4 | |a National Organization for Rare Disorders | |
| 650 | 4 | |a extraordinary pricing | |
| 650 | 4 | |a Corporate Social Responsibility | |
| 650 | 4 | |a Biotechnology Industry Organization | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of business ethics |d Dordrecht : Springer, 1982 |g 94(2010), 2, Seite 225-242 |h Online-Ressource |w (DE-627)270937129 |w (DE-600)1478688-6 |w (DE-576)121465284 |x 1573-0697 |7 nnas |
| 773 | 1 | 8 | |g volume:94 |g year:2010 |g number:2 |g pages:225-242 |
| 856 | |3 Volltext |u http://www.jstor.org/stable/40784598 |x JSTOR | ||
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10551-009-0259-x |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 883 | |8 1 |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 935 | |a mteo | ||
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4033697667 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1785638785 | ||
| LOK | |0 005 20220112043721 | ||
| LOK | |0 008 220112||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2021-12-30#9DACA18AF03A89A49BAF07D6657482AB85143C8A | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 866 |x JSTOR#http://www.jstor.org/stable/40784598 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||
| STA | 0 | 0 | |a Corporate social responsibility |
| STB | 0 | 0 | |a Responsabilité sociale de l'entreprise |
| STC | 0 | 0 | |a Responsabilidad social de la empresa |
| STD | 0 | 0 | |a Corporate social responsibility,Responsabilità sociale d'impresa,Responsabilità sociale d'impresa |
| STF | 0 | 0 | |a 企業社會責任 |
| STG | 0 | 0 | |a Responsabilidade social da empresa |
| STH | 0 | 0 | |a Корпоративная социальная ответственность |
| STI | 0 | 0 | |a Εταιρική κοινωνική ευθύνη,Corporate social responsibility |
| SYE | 0 | 0 | |a Corporate social responsibility,Corporate citizenship,Corporate environment responsibility,Corporate environmental responsibility,Corporate responsibility,Corporate sustainability management,Corporate volunteering,CSR (Corporate social responsibility),Environment social governance,Environmental, social and corporate governance,Environmental, social and governance,ESG,Gesellschaftliche Unternehmensverantwortung,Gesellschaftliche Verantwortung von Unternehmen,Gesellschaftliches Engagement von Unternehmen,Nachhaltigkeitsmanagement,Soziale Verantwortung von Unternehmen,Soziales Engagement von Unternehmen,Unternehmensverantwortung,Unternehmerische Sozialverantwortung,CSR,Corporate Citizenship,Unternehmerische Gesellschaftsverantwortung,Unternehmerische Sozialverantwortung,Unternehmen |
